Intravenous nitroglycerin was historically produced by three manufacturers: Hospira, Luitpold/American Regent and Baxter. However, Baxter is now the sole manufacturer of the drug for the U.S. markets due to “manufacturing problems” with the other two companies, according to the report.
Baxter has recently reported issues with manufacturing, lessening their supply, according to the report.
“[The U.S. Food and Drug Administration] continues to work with Baxter to address and resolve the shortage and continues to work with Hospira and American Regent as well, since we would like to have all manufacturers back on the market,” said Christopher Kelly from the FDA’s office of media affairs, in the report.
More Articles on Drug Shortages:
AHA Seeks FDA Action on Saline, IV Solution Shortage
8 Statistics on Care Affected by Drug Shortages
FDA Works to Ease National Saline Shortage
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.